Autoimmune Hepatitis Model
Autoimmune Hepatitis Model - Related Videos
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
0 Views •
Cited by 31 •
2012
Infection of mice with an Adenovirus expressing the major human autoantigen cytochrome P450 2D6 (hCYP2D6) recognized by sera of patients suffering from type 2 autoimmune hepatitis results in a persistent form of autoimmune-mediated liver disease characterized by extensive hepatitis, fibrosis and generation of a CYP2D6-specific immune response.
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
0 Views •
Cited by 10 •
2012
An optical system was developed to visualize hepatic microcirculation with FITC-labeled erythrocytes and to measure the partial pressure of oxygen in the microvessels with laser-assisted phosphorimetry. This method can be used to investigate physiological and pathological mechanisms by analyzing microvascular structure, diameter, blood flow velocity, and oxygen tension.
05:23
Murine Bioluminescent Hepatic Tumour Model
0 Views •
Cited by 11 •
2010
This article describes a procedure for the induction of orthotopic bioluminescent liver tumours in mice, and subsequent analysis of tumour growth confined to the liver using live whole body luminescence imaging.
01:55
Assessment of Cornea and Tear Smoothness in an Autoimmune Dry Eye Rat Model
0 Views •
2025
This video demonstrates a method for assessing corneal smoothness and tear film stability in an autoimmune rat model. It highlights the impact of gland dysfunction on tear film stability, crucial for understanding dry eye disease.
FAQs
Loss of immune tolerance permits immune recognition of liver components that would normally remain protected from attack. Autoreactive immune cells then become activated and direct inflammation toward hepatocytes, while inflammatory signals amplify tissue injury. Modeling this sequence helps researchers connect an initiating failure in immune regulation with measurable liver damage and investigate where therapeutic intervention may interrupt disease progression.
Autoreactive immune cells provide the liver-directed immune response, whereas inflammatory signals help sustain and intensify that response. Their interaction promotes hepatocellular injury rather than an isolated, transient immune event. Examining both components is important because a model can reveal whether disease features arise from immune-cell activation, inflammatory amplification, or the combined effects of these mechanisms.
Fibrosis indicates that repeated or sustained liver injury has produced structural changes in hepatic tissue. Including fibrosis among model outcomes extends analysis beyond short-term inflammation and shows whether immune-mediated damage is associated with progressive tissue remodeling. This makes fibrosis useful for evaluating the longer-term consequences of disease mechanisms and for testing approaches intended to limit liver damage.
The models support two complementary therapeutic strategies. One approach aims to restore immune regulation and reduce the autoreactive response at its source. Another focuses on limiting hepatocellular injury and the tissue damage that follows. Comparing these strategies helps researchers determine whether an intervention primarily changes immune mechanisms, protects liver tissue, or addresses both aspects of disease.
Evaluation should connect immune activity with changes in liver tissue and function. Relevant outcomes supported by the model include liver-directed inflammation, hepatocellular injury, fibrosis, immune responses, and measurable changes in liver function. Considering these outcomes together provides a more informative assessment than examining immune activation or tissue damage alone, because it links mechanism with disease expression.
Researchers use these systems to examine biological changes associated with immune-mediated liver injury and identify candidate biomarkers of disease activity or progression. The same models can then support treatment evaluation by testing whether an intervention restores immune regulation or limits liver damage. Their value lies in connecting mechanistic findings with measurable tissue and functional outcomes relevant to therapeutic development.